Optimizing Blood Pressure Control: A Randomized Comparative Trial of Losartan/Chlorthalidone vs. Losartan/Hydrochlorothiazide
Abstract Introduction Cardiovascular diseases are a leading cause of global mortality, with hypertension as a major risk factor. Low control rates are often attributed to monotherapy, while evidence and clinical guidelines support the effectiveness of combination therapies. This study aimed to evalu...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-04-01
|
| Series: | Cardiology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40119-025-00407-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849725153783578624 |
|---|---|
| author | Isabel E. Rucker-Joerg Ernesto G. Cardona-Muñoz Francisco G. Padilla-Padilla Rodrigo Suarez-Otero Yulia Romero-Antonio Emmanuel Canales-Vázquez Kevin F. Rios-Brito Ileana C. Rodríguez-Vazquez Jorge González-Canudas |
| author_facet | Isabel E. Rucker-Joerg Ernesto G. Cardona-Muñoz Francisco G. Padilla-Padilla Rodrigo Suarez-Otero Yulia Romero-Antonio Emmanuel Canales-Vázquez Kevin F. Rios-Brito Ileana C. Rodríguez-Vazquez Jorge González-Canudas |
| author_sort | Isabel E. Rucker-Joerg |
| collection | DOAJ |
| description | Abstract Introduction Cardiovascular diseases are a leading cause of global mortality, with hypertension as a major risk factor. Low control rates are often attributed to monotherapy, while evidence and clinical guidelines support the effectiveness of combination therapies. This study aimed to evaluate blood pressure changes and the achievement of target levels in patients treated with losartan/chlorthalidone (L/C) compared to losartan/hydrochlorothiazide (L/H). Methods A randomized, double-blind, prospective, multicenter clinical trial was conducted. Patients were assigned to one of two treatment groups, starting with a lower dose (50/12.5 mg of losartan/chlorthalidone or losartan/hydrochlorothiazide). Blood pressure was evaluated at 30 days, and patients not meeting therapeutic goals were escalated to a higher dose (100/50 mg of losartan/chlorthalidone or losartan/hydrochlorothiazide) and followed until the study end (60 days). Results The study recruited 163 patients (83 for losartan/chlorthalidone [L/C] group and 80 for the losartan/hydrochlorothiazide [L/H] group), with a mean age of 53.1 years. Both treatment groups demonstrated significant reductions in systolic and diastolic blood pressure, with L/C achieving an average reduction in systolic blood pressure (SBP) of − 24.6 mmHg and − 13.3 mmHg for diastolic blood pressure (DBP), while L/H had reductions of − 25.3-mmHg and − 11.5 mmHg, respectively. The L/C group exhibited a higher likelihood of achieving blood pressure goals compared to the L/H. Adverse events were comparable between groups and were mostly mild. Conclusions The study showed that both combinations are effective for hypertension, with losartan/chlorthalidone demonstrating greater efficacy in reducing diastolic blood pressure and achieving target levels. Both treatments exhibited similar and favorable safety profiles. Clinical Trials Registration NCT04927299. Registered August 6, 2021- https://clinicaltrials.gov/study/NCT04927299 |
| format | Article |
| id | doaj-art-d44bfb7c8df646d3bceafe03418c07e7 |
| institution | DOAJ |
| issn | 2193-8261 2193-6544 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Cardiology and Therapy |
| spelling | doaj-art-d44bfb7c8df646d3bceafe03418c07e72025-08-20T03:10:32ZengAdis, Springer HealthcareCardiology and Therapy2193-82612193-65442025-04-0114223124710.1007/s40119-025-00407-7Optimizing Blood Pressure Control: A Randomized Comparative Trial of Losartan/Chlorthalidone vs. Losartan/HydrochlorothiazideIsabel E. Rucker-Joerg0Ernesto G. Cardona-Muñoz1Francisco G. Padilla-Padilla2Rodrigo Suarez-Otero3Yulia Romero-Antonio4Emmanuel Canales-Vázquez5Kevin F. Rios-Brito6Ileana C. Rodríguez-Vazquez7Jorge González-Canudas8Clinical Research InstitutePrivate PracticeClinical and Intervenrional CardiologyPrivate PracticeLaboratorios Silanes, S.A. de C.V.Laboratorios Silanes, S.A. de C.V.Laboratorios Silanes, S.A. de C.V.Laboratorios Silanes, S.A. de C.V.Laboratorios Silanes, S.A. de C.V.Abstract Introduction Cardiovascular diseases are a leading cause of global mortality, with hypertension as a major risk factor. Low control rates are often attributed to monotherapy, while evidence and clinical guidelines support the effectiveness of combination therapies. This study aimed to evaluate blood pressure changes and the achievement of target levels in patients treated with losartan/chlorthalidone (L/C) compared to losartan/hydrochlorothiazide (L/H). Methods A randomized, double-blind, prospective, multicenter clinical trial was conducted. Patients were assigned to one of two treatment groups, starting with a lower dose (50/12.5 mg of losartan/chlorthalidone or losartan/hydrochlorothiazide). Blood pressure was evaluated at 30 days, and patients not meeting therapeutic goals were escalated to a higher dose (100/50 mg of losartan/chlorthalidone or losartan/hydrochlorothiazide) and followed until the study end (60 days). Results The study recruited 163 patients (83 for losartan/chlorthalidone [L/C] group and 80 for the losartan/hydrochlorothiazide [L/H] group), with a mean age of 53.1 years. Both treatment groups demonstrated significant reductions in systolic and diastolic blood pressure, with L/C achieving an average reduction in systolic blood pressure (SBP) of − 24.6 mmHg and − 13.3 mmHg for diastolic blood pressure (DBP), while L/H had reductions of − 25.3-mmHg and − 11.5 mmHg, respectively. The L/C group exhibited a higher likelihood of achieving blood pressure goals compared to the L/H. Adverse events were comparable between groups and were mostly mild. Conclusions The study showed that both combinations are effective for hypertension, with losartan/chlorthalidone demonstrating greater efficacy in reducing diastolic blood pressure and achieving target levels. Both treatments exhibited similar and favorable safety profiles. Clinical Trials Registration NCT04927299. Registered August 6, 2021- https://clinicaltrials.gov/study/NCT04927299https://doi.org/10.1007/s40119-025-00407-7HypertensionCardiovascular diseaseLosartanChlorthalidoneHydrochlorothiazide |
| spellingShingle | Isabel E. Rucker-Joerg Ernesto G. Cardona-Muñoz Francisco G. Padilla-Padilla Rodrigo Suarez-Otero Yulia Romero-Antonio Emmanuel Canales-Vázquez Kevin F. Rios-Brito Ileana C. Rodríguez-Vazquez Jorge González-Canudas Optimizing Blood Pressure Control: A Randomized Comparative Trial of Losartan/Chlorthalidone vs. Losartan/Hydrochlorothiazide Cardiology and Therapy Hypertension Cardiovascular disease Losartan Chlorthalidone Hydrochlorothiazide |
| title | Optimizing Blood Pressure Control: A Randomized Comparative Trial of Losartan/Chlorthalidone vs. Losartan/Hydrochlorothiazide |
| title_full | Optimizing Blood Pressure Control: A Randomized Comparative Trial of Losartan/Chlorthalidone vs. Losartan/Hydrochlorothiazide |
| title_fullStr | Optimizing Blood Pressure Control: A Randomized Comparative Trial of Losartan/Chlorthalidone vs. Losartan/Hydrochlorothiazide |
| title_full_unstemmed | Optimizing Blood Pressure Control: A Randomized Comparative Trial of Losartan/Chlorthalidone vs. Losartan/Hydrochlorothiazide |
| title_short | Optimizing Blood Pressure Control: A Randomized Comparative Trial of Losartan/Chlorthalidone vs. Losartan/Hydrochlorothiazide |
| title_sort | optimizing blood pressure control a randomized comparative trial of losartan chlorthalidone vs losartan hydrochlorothiazide |
| topic | Hypertension Cardiovascular disease Losartan Chlorthalidone Hydrochlorothiazide |
| url | https://doi.org/10.1007/s40119-025-00407-7 |
| work_keys_str_mv | AT isabeleruckerjoerg optimizingbloodpressurecontrolarandomizedcomparativetrialoflosartanchlorthalidonevslosartanhydrochlorothiazide AT ernestogcardonamunoz optimizingbloodpressurecontrolarandomizedcomparativetrialoflosartanchlorthalidonevslosartanhydrochlorothiazide AT franciscogpadillapadilla optimizingbloodpressurecontrolarandomizedcomparativetrialoflosartanchlorthalidonevslosartanhydrochlorothiazide AT rodrigosuarezotero optimizingbloodpressurecontrolarandomizedcomparativetrialoflosartanchlorthalidonevslosartanhydrochlorothiazide AT yuliaromeroantonio optimizingbloodpressurecontrolarandomizedcomparativetrialoflosartanchlorthalidonevslosartanhydrochlorothiazide AT emmanuelcanalesvazquez optimizingbloodpressurecontrolarandomizedcomparativetrialoflosartanchlorthalidonevslosartanhydrochlorothiazide AT kevinfriosbrito optimizingbloodpressurecontrolarandomizedcomparativetrialoflosartanchlorthalidonevslosartanhydrochlorothiazide AT ileanacrodriguezvazquez optimizingbloodpressurecontrolarandomizedcomparativetrialoflosartanchlorthalidonevslosartanhydrochlorothiazide AT jorgegonzalezcanudas optimizingbloodpressurecontrolarandomizedcomparativetrialoflosartanchlorthalidonevslosartanhydrochlorothiazide |